Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.

Abstract: The process of the present invention creates a sustainable and closed water loop allowing inherent recycles of all liquid streams generated in the process. The liquid streams generated during the process of the invention are inherently recycled completely, making the process of the present invention a zero liquid discharge process which is environmentally friendly and sustainable. This invention further relates to a sustainable chemical process of reduction of R—NO2 or R—NO into corresponding R—NH2 that produces environmentally friendly R—NH2 in good yields and selectivity with large of mother liquor recycle. The process has a wide scope in that it can be applied to a number of molecules.

Abstract: Process for the manufacture of 1,2-dichloroethane starting with a hydrocarbon source according to which: a) the hydrocarbon source is subjected to cracking which produces a mixture of products containing ethylene and other constituents; b) the mixture of products containing ethylene is conveyed to at least one storage reservoir; c) a chlorination reactor and/or an oxychlorination reactor is (are) supplied with the previously stored mixture of products containing ethylene, in which reactors most of the ethylene present is converted to 1,2-dichloroethane; d) the 1,2-dichloroethane obtained is separated from the streams of products derived from the chlorination and oxychlorination reactors.

Abstract: The present invention relates to a method of reducing the total organic carbon (TOC) content of waste water in the course of the preparation of concentrated solutions or suspensions of anionic organic compounds, which method comprises increasing the concentration of an aqueous solution or suspension of an anionic organic compound in the form of its free acid or its alkali metal salt, having a salt content of less than 5% of extraneous salt by weight based on the total solution or suspension, by microfiltration, ultrafiltration and/or nanofiltration, a) the membrane pore size being so selected that compounds having molecular weights in the range from 300 to 1000 Daltons or higher are retained, and b) the content of anionic compound in the concentrate being so adjusted to from 10 to 50% by weight that the total organic carbon (TOC) content of the permeate is less than 0.

Abstract: An aromatic amino sulfonic acid compound is purified by a process including steps of:(a) dissolving the aromatic amino sulfonic acid compound in aqueous medium having a basic pH;(b) acidifying the aqueous medium with acetic acid to precipitate the aromatic amino sulfonic acid compound; and(c) removing the precipitated aromatic amino sulfonic acid compound from the aqueous medium.Using acetic acid in the process results in removal of more impurities and undesirable sulfate and chloride salts to provide an improved material for synthesizing dyes and pigments.

Abstract: 2,4-disulfonyl .alpha.-phenyl-tert-butyl nitrone and its pharmaceutically acceptable salts are disclosed. These materials are useful as pharmaceutical agents for oral or parenteral, e.g. intravenous administration to patients suffering from acute central nervous system oxidation as occurs in a stroke or from gradual central nervous system oxidation which can exhibit itself as progressive central nervous system function loss. The materials are also used to ameliorate the side effects of oxidative-damage causing antineoplastic disease treatments.

Abstract: A method of producing 4-ADPA is disclosed wherein aniline or substituted aniline derivatives and nitrobenzene are reacted under suitable conditions to produce 4-nitrodiphenylamine or substituted derivatives thereof and/or 4-nitrosodiphenylamine or substituted derivatives thereof and/or their salts, either or both of which are subsequently reduced to produce 4-ADPA or substituted derivatives thereof. The 4-ADPA or substituted derivatives thereof can be reductively alkylated to produce p-phenylenediamine products or substituted derivatives thereof which are useful as antiozonants.

Abstract: A suspension polymerization of a polymerizable monomer in the presence of an emulsion polymerization inhibitor is disclosed. The inhibitor is an aromatic series compound having a NO.sub.2 group, a SO.sub.3 Na group, and a secondary amino group, representatively, the following compound. In this suspension polymerization, the production of by-produced microfine particles caused by the emulsion polymerization as the secondary polymerization scheme is repressed.

Abstract: The reaction product of:(a) a compound of the formula: ##STR1## wherein X is a member selected from the group consisting of N, O and S; R.sub.1 and R.sub.2 are independently a straight or branched, saturated or unsaturated non-aromatic hydrocarbon of four to eighteen carbon atoms; m is 1 or 2; and n is 0, 1 or 2; and(b) a compound selected from the group consisting of primary, secondary, tertiary and higher amines, which are liquid at room temperature.The reaction product of the present invention has excellent surfactant properties, and is suitable for use in coloring compositions to improve the fugitivity from skin and clothing. The reaction product is also useful as a cleansing agent.

Abstract: 2,4-disulfonyl .alpha.-phenyl-tert-butyl nitrone and its pharmaceutically acceptable salts are disclosed. These materials are useful as pharmaceutical agents for oral or intravenous administration to patients suffering from acute central nervous system oxidation as occurs in a stroke or from gradual central nervous system oxidation which can exhibit itself as progressive central nervous system function loss.

Abstract: 2,4-disulfonyl .alpha.-phenyl-tert-butyl nitrone and its pharmaceutically acceptable salts are disclosed. These materials are useful as pharmaceutical agents for oral or parenteral, e.g. intravenous administration to patients suffering from acute central nervous system oxidation as occurs in a stroke or from gradual central nervous system oxidation which can exhibit itself as progressive central nervous system function loss. The materials are also used to ameliorate the side effects of oxidative-damage causing antineoplastic disease treatments.

Abstract: Diazonium compounds are disclosed which correspond to the formula ##STR1## in which Y' is vinyl, .beta.-hydroxyethyl of an ethyl group having a substituent in the .beta.-position which is eliminated by means of alkali, R is hydrogen, hydroxy, alkyl having 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, carboxy or halogen, n is the number 0, 1 or 2, M is hydrogen or an alkali metal, and An is an anion, and wherein the diazonium group is bound in the meta- or para-position to the nitrogen of the benzotriazole radical.Also disclosed is a process for the preparation of the diazonium compounds. The compounds are useful as diazo components for the preparation of azo compounds by a coupling reaction.